单位：[1]Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China[2]Department of Pharmacy, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China北京朝阳医院[3]College of Pharmacy and Health Sciences, Western New England University, Springfield, MA, USA[4]Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA[5]Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China医技科室药学部首都医科大学附属北京友谊医院[6]Institute for Drug Evaluation, Peking University Health Science Center, Beijing, China
Background A recent study is raising concerns that dipeptidyl peptidase 4 inhibitors are associated with increased risk of venous thromboembolism. Objective We aimed to assess the association between dipeptidyl peptidase-4 inhibitors and venous thromboembolism using the US Food and Drug Administration Adverse Event Reporting System database. Methods We searched the venous thromboembolism cases related to dipeptidyl peptidase-4 inhibitors from 2004 first quarter to 2018 first quarter. We compared dipeptidyl peptidase-4 inhibitors versus three groups: (1) all other glucose-lowering drugs excluding insulins; (2) sulfonylureas and sodium-glucose-cotransporter-2 inhibitors; (3) sodium-glucose-cotransporter-2 inhibitors. In each comparison, we calculated proportional rate ratios and 95% confidence ratios by SAS 9.4. Results We obtained 873 dipeptidyl peptidase-4 inhibitors-associated venous thromboembolism events. Compared to all other glucose lowering-drugs excluding insulins, the proportional reporting ratio for overall venous thromboembolism, deep vein thrombosis, pulmonary embolism were 0.92 (0.86, 0.99), 0.91 (0.82,1.01), and 0.82 (0.74,0.90), respectively; the proportional reporting ratio for portal vein thrombosis, splenic vein thrombosis, mesenteric vein thrombosis were 3.94 (2.96, 5.25), 10.80 (6.14, 18.99), and 4.98 (2.76,8.96), respectively. Conclusion Our analysis found no association between dipeptidyl peptidase-4 inhibitors and venous thromboembolism risk, while moderate to strong signals of portal vein thrombosis, splenic vein thrombosis, mesenteric vein thrombosis risks were observed.
基金：
School of Pharmaceutical Sciences, Peking University [69003Y0052]
第一作者单位：[1]Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China[2]Department of Pharmacy, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
通讯作者：
推荐引用方式(GB/T 7714)：
Lu Wenchao,Sun Shusen,Wei Jingkai,et al.Dipeptidyl peptidase-4 inhibitors and risk of venous thromboembolism: data mining of FDA adverse event reporting system[J].INTERNATIONAL JOURNAL of CLINICAL PHARMACY.2020,42(5):1364-1368.doi:10.1007/s11096-020-01037-w.
APA：
Lu, Wenchao,Sun, Shusen,Wei, Jingkai,Thai, Sydney,Li, Dandan...&Sun, Lulu.(2020).Dipeptidyl peptidase-4 inhibitors and risk of venous thromboembolism: data mining of FDA adverse event reporting system.INTERNATIONAL JOURNAL of CLINICAL PHARMACY,42,(5)
MLA：
Lu, Wenchao,et al."Dipeptidyl peptidase-4 inhibitors and risk of venous thromboembolism: data mining of FDA adverse event reporting system".INTERNATIONAL JOURNAL of CLINICAL PHARMACY 42..5(2020):1364-1368
